Vectura Group Liabilities 2024

Vectura Group Aktienanalyse

What does Vectura Group do?

The Vectura Group PLC is a British company specializing in the development of inhalable medications. The company was founded in 1997 and is headquartered in Chippenham, England. History: Initially, Vectura focused on the development of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). In 2014, the company acquired competitor Skyepharma, expanding its product range to include a wider spectrum of inhalable medications and active ingredients. Business Model: Vectura's business model is based on collaborating with its partners to develop inhalable therapies and active ingredients. The company itself acts as a service provider, offering support to the pharmaceutical industry in the development of new solutions. Vectura has a wide range of technologies and expertise to offer its customers tailored solutions. Divisions: Vectura is divided into four different business units. "Inhaled Therapies" offers solutions for inhaling medications, including inhalers equipped with special propellants to deliver the active ingredients directly to the lungs. The "Royalty-Driven Products" division includes products for which Vectura holds licenses and benefits from the sales of these products. In the "Device Services" division, the company offers development and design services for inhalable therapies. Finally, Vectura also has a research department referred to as "New Product Opportunities," where the company works on the development of new technologies and therapies. Products: Vectura's key products include treatments for asthma and COPD, such as the inhaler Flutiform and the medication Seebri. The company also offers inhalable therapies for other diseases, such as cystic fibrosis and pulmonary hypertension. In addition to medical applications, Vectura also develops more sustainable inhalers and devices that do not rely on chlorofluorocarbons (CFCs) or other environmentally harmful propellants. Conclusion: Vectura has established itself as one of the leading companies in the field of inhalable medications. The company offers tailored solutions for its customers and invests in the development of new technologies to enhance inhalation therapy. Vectura has expanded its portfolio in recent years through the acquisition of Skyepharma and aims to further expand its market position. Vectura Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Vectura Group's Liabilities

Vectura Group's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vectura Group's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vectura Group's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vectura Group's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vectura Group’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vectura Group stock

What is the level of liabilities of Vectura Group this year?

Vectura Group has a debt balance of 0 GBP this year.

What were the liabilities of Vectura Group compared to the previous year?

The liabilities of Vectura Group have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of Vectura Group?

High liabilities can pose a risk for investors of Vectura Group, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Vectura Group?

Low liabilities mean that Vectura Group has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Vectura Group affect the company?

An increase in liabilities of Vectura Group can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Vectura Group affect the company?

A decrease in the liabilities of Vectura Group can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Vectura Group?

Some factors that can influence the liabilities of Vectura Group include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Vectura Group so important for investors?

The liabilities of Vectura Group are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Vectura Group take to modify the liabilities?

To change its liabilities, Vectura Group can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Vectura Group pay?

Over the past 12 months, Vectura Group paid a dividend of 0.06 GBP . This corresponds to a dividend yield of about 3.64 %. For the coming 12 months, Vectura Group is expected to pay a dividend of 0 GBP.

What is the dividend yield of Vectura Group?

The current dividend yield of Vectura Group is 3.64 %.

When does Vectura Group pay dividends?

Vectura Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vectura Group?

Vectura Group paid dividends every year for the past 0 years.

What is the dividend of Vectura Group?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vectura Group located?

Vectura Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vectura Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vectura Group from 6/11/2021 amounting to 0.19 GBP, you needed to have the stock in your portfolio before the ex-date on 6/1/2021.

When did Vectura Group pay the last dividend?

The last dividend was paid out on 6/11/2021.

What was the dividend of Vectura Group in the year 2023?

In the year 2023, Vectura Group distributed 0 GBP as dividends.

In which currency does Vectura Group pay out the dividend?

The dividends of Vectura Group are distributed in GBP.